肥厚型心肌病临床实践指南的执行摘要为临床医生诊断和管理成人和儿科患者的肥厚型心肌病提供了建议和算法,并提供了支持文档以鼓励其使用。
从2010年1月1日至2020年4月30日进行了全面的文献检索,包括研究,reviews,以及PubMed以英文发表的关于人类受试者的其他证据,EMBASE,科克伦合作组织,机构的医疗保健研究和质量报告,和其他相关数据库。
早期肥厚型心肌病指南中的许多建议已经更新,有了新的证据或对早期证据的更好理解。本摘要将完整指南中的建议付诸实施,并提出了诊断工作的组合,遗传和家庭筛查,风险分层方法,改变生活方式,手术和导管干预,以及构成指南指导药物治疗组成部分的药物。对于指南指导的药物治疗和其他推荐的药物治疗方案,建议读者遵循剂量,基于产品插页材料的禁忌症和药物相互作用。
This executive summary of the hypertrophic cardiomyopathy clinical practice
guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use.
A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases.
Many recommendations from the earlier hypertrophic cardiomyopathy
guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full
guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of
guideline directed medical therapy. For both
guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.